RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure–response relationship
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-0843
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure–response relationship ; volume:90 ; number:2 ; day:16 ; month:7 ; year:2022 ; pages:137-148 ; date:8.2022
Cancer chemotherapy and pharmacology ; 90, Heft 2 (16.7.2022), 137-148, 8.2022
- Creator
-
Nakagawa, Kazuhiko
Garon, Edward B.
Gao, Ling
Callies, Sophie
Zimmermann, Annamaria
Walgren, Richard
Visseren-Grul, Carla
Reck, Martin
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00280-022-04447-x
- URN
-
urn:nbn:de:101:1-2022102421272855791790
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:36 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Nakagawa, Kazuhiko
- Garon, Edward B.
- Gao, Ling
- Callies, Sophie
- Zimmermann, Annamaria
- Walgren, Richard
- Visseren-Grul, Carla
- Reck, Martin
- SpringerLink (Online service)
Other Objects (12)
RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability
Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell Lung Cancer in the RELAY Study
Erlotinib in pancreatic cancer
Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials
A mixed treatment comparison of Erlotinib vs. placebo and Erlotinib vs. Geftinib using Bayesian approaches
Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national database
A Real-World Analysis of Patients with Untreated Metastatic Epidermal Growth Factor Receptor (EGFR)-Mutated Lung Adenocarcinoma Receiving First-Line Erlotinib and Bevacizumab Combination Therapy
Functionalized MoS2-erlotinib produces hyperthermia under NIR
Perifollicular Xanthoma Occurring in Patients after Erlotinib Treatment
Erlotinib Plus Bevacizumab Phase ll Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines
Ramucirumab (NSCLC, Kombination mit Erlotinib) : Nutzenbewertung gemäß § 35a SGB V
RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability
Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell Lung Cancer in the RELAY Study
Erlotinib in pancreatic cancer
Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials
A mixed treatment comparison of Erlotinib vs. placebo and Erlotinib vs. Geftinib using Bayesian approaches
Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national database
A Real-World Analysis of Patients with Untreated Metastatic Epidermal Growth Factor Receptor (EGFR)-Mutated Lung Adenocarcinoma Receiving First-Line Erlotinib and Bevacizumab Combination Therapy
Functionalized MoS2-erlotinib produces hyperthermia under NIR
Perifollicular Xanthoma Occurring in Patients after Erlotinib Treatment
Erlotinib Plus Bevacizumab Phase ll Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines
Ramucirumab (NSCLC, Kombination mit Erlotinib) : Nutzenbewertung gemäß § 35a SGB V
RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability
Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell Lung Cancer in the RELAY Study
Erlotinib in pancreatic cancer
Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials
A mixed treatment comparison of Erlotinib vs. placebo and Erlotinib vs. Geftinib using Bayesian approaches
Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national database
A Real-World Analysis of Patients with Untreated Metastatic Epidermal Growth Factor Receptor (EGFR)-Mutated Lung Adenocarcinoma Receiving First-Line Erlotinib and Bevacizumab Combination Therapy
Functionalized MoS2-erlotinib produces hyperthermia under NIR
Perifollicular Xanthoma Occurring in Patients after Erlotinib Treatment
Erlotinib Plus Bevacizumab Phase ll Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines